Thrombocytopenia and grade 2 anaemia were reported in 27% and 18% of patients treated with anti-CD19 + nivolumab [30] and grade 3 in 58% and 47% of patients treated with anti-CD19/22 + pembrolizumab [34], both chemotherapy associated. This evidence concerns the gene CD19 and anemia.